Company Celltrion, Inc. Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
86.1
%
| 1,937,469 | 84.8 % | 1,873,430 | 86.1 % | -3.31% |
Chemical Drugs
23.0
%
| 653,519 | 28.6 % | 500,777 | 23.0 % | -23.37% |
Reconciling Items
-9.3
%
| -310,898 | -13.6 % | -202,919 | -9.3 % | -34.73% |
Others
0.2
%
| 3,877 | 0.2 % | 5,143 | 0.2 % | +32.66% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
97.1
%
| 2,090,465 | 91.5 % | 2,113,156 | 97.1 % | +1.09% |
Asia
2.9
%
| 62,069 | 2.7 % | 63,275 | 2.9 % | +1.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Sung-Han Lee
CMP | Compliance Officer | 42 | - |
Yoon-Mo Koo
PRN | Corporate Officer/Principal | 54 | - |
Sang-Joon Lee
PRN | Corporate Officer/Principal | 57 | - |
Shin-Jae Jang
PRN | Corporate Officer/Principal | 60 | - |
Jung-Won Yoon
PRN | Corporate Officer/Principal | 57 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jong-Seok Lee
BRD | Director/Board Member | 72 | 14-12-07 |
Joseph Lee
BRD | Director/Board Member | 66 | 08-07-16 |
Gyun-Seok Cho
BRD | Director/Board Member | 64 | 09-03-19 |
Byung-Hoon Jeon
BRD | Director/Board Member | 66 | 14-03-26 |
Geun-Young Kim
BRD | Director/Board Member | 64 | - |
Dae-Hyeon Yoo
BRD | Director/Board Member | 65 | - |
Min-Cheol Shin
BRD | Director/Board Member | 61 | - |
Hyeok-Jae Lee
BRD | Director/Board Member | 48 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 215,109,440 | 141,993,143 ( 66.01 %) | 11,199,208 ( 5.206 %) | 66.01 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CELLTRION PHARM, INC. 54.82% | 22,797,613 | 54.82% | 1,585,160,663 $ |
CELLTRION, INC. 2.07% | 4,508,124 | 2.07% | 616,478,879 $ |
BIOTOXTECH CO., LTD. 10.22% | 1,631,134 | 10.22% | 6,609,045 $ |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock
- Company Celltrion, Inc.